CardioDiagnostics - Reinventing Cardiac Care

Time 2020-12-28 05:03:18

Web Name: CardioDiagnostics - Reinventing Cardiac Care

WebSite: http://www.cardiodiagnostics.net

ID:148495

Keywords:

Reinventing,CardioDiagnostics,Care,

Description:

The World's First HIPAA-Compliant Cloud-Based Cardiac Monitoring Solution Learn More CardioDiagnostics is a medical technology company specialized in data analytics and bringing cutting-edge Mobile Cardiac Telemetry technology to the International Market. Established in USA with global R&D offices, the company develops proprietary technologies to monitor patients' hearts wirelessly. Our team of experts is working together to meet the market needs and solve existing problems in the cardiac care industry through research-based pioneering technologies. CardioDiagnostics is focused on creating Remote Cardiac Monitoring technologies in the aim of treating patients with cardiac problems. Patients may continue normal day-to-day lifestyle, while CardioDiagnostics makes sure that physicians receive vital cardiac information needed to make a proper diagnosis. We envision a world where cardiac disease is no longer the leading cause of death around the world. Our mission is to reinvent cardiac care through world-class pioneering technologies. On Monday, May 11, 2015, U.S. President Barack Obama recognized Ziad Sankari, Founder of CardioDiagnostics, as a Pioneer, appreciating his company’s work in helping to save lives. “Thank you Ziad for helping us save lives” Lifesense Arrhythmia is an advanced wireless monitoring solution using FDA-approved devices equipped with proprietary algorithms to automatically record, detect and transmit wirelessly a wide range of cardiac events, allowing physicians to monitor patients continuously, in real-time, for up to 30 days. Many arrhythmias do not occur frequently enough to be detected using the current monitoring technologies such as Holters, Event monitors, etc. Patients with such arrhythmias require efficient and reliable long-term continuous real-time monitoring. Lifesense Arrhythmia allows patients to be monitored off-hospital around the clock using convenient, non-intrusive monitoring devices that transmit data remotely in real-time. It has a hardware-agnostic module offering multiple hardware options to ensure the patients’ compliance and the customers’ satisfaction. Lifesense aims at monitoring different types of arrhythmias: The ECG, the location, and other vital information are wirelessly transmitted to a dedicated monitoring center where professional medical experts evaluate the events, and respond accordingly. Physicians are able to access real-time patient data from any internet-connected device. There are 2 types of data transmission : Automatic transmission: The device automatically detects an abnormality. This is ideal for symptomatic and asymptomatic events. Patient-triggered transmission: Ideal for correlating symptomatic and auto-triggered events. Patients may input their symptoms and activity levels. The device itself is about the weight and size of a mobile phone and comes with a pouch, so patients can wear it on a belt or attach it to their wrist. Patients can go about their normal routine with it on, even exercising or traveling, and they can charge the device while still wearing it. READ MORE CloudBeat Software is designed to provide the best user experience in reviewing and analyzing cardiac data. It empowers medical staff to make a fast and proper diagnosis, while patients comfortably continue their daily life routine. CloudBeat is the World’s 1st HIPAA-Compliant, Hardware-Agnostic Cloud-Based Cardiac Monitoring System accessible from any internet-connected device. For more information, please feel free to check our Software Brochure and Contact us now. We understand how it feels to live with anxiety and uncertainty. It is our mission to fully attain your comfort and well-being. For that purpose, we have created medical technologies to help you receive the most accurate cardiac diagnosis, and to live a longer and healthier life. The patient care personnel are trained to provide you with support 24-hours a day, 7-days a week to ensure all your questions and concerns are resolved promptly. You can find our solutions in multiple monitoring centers around the U.S. Please Contact Us to refer you to your nearest monitoring center. "Here I am in California, in Los Angeles, the patient could be in Los Angeles or could be in Hawaii or Thailand, and I could still monitor that patient through the cloud. It is a life-changing event for a patient in terms of reassurance that they’re going to be OK." To facilitate your role in properly diagnosing your cardiac patients, we have created the World's First HIPAA-Compliant, Secure, Cloud-Based Cardiac Management System that is accessible from any internet-connected device. Being hardware-agnostic, with an intuitive design and a customizable workflow, our platform has allowed many of our partners in the US to diagnose a larger group of cardiac applications, in a timely manner. As a partnering monitoring center, you will benefit from our world class training services that we provide to your patient care personnel, to ensure that patients are receiving the most adequate and relevant diagnosis they need. For more information, please feel free to check our Software Brochure and Contact us now. The global cardiac monitoring and cardiac rhythm management devices market is estimated to reach 26.65 billion US$ by 2020, and Mobile Cardiac Telemetry has been increasingly playing a major role in addressing this market's needs. ― Markets and Markets Moreover, Studies have proven that the diagnostic yield of patients monitored with MCT (Mobile Cardiac Telemetry) is significantly higher than the diagnostic yield of patients that use the Event monitor, or the Holter Monitor. With MCT gaining superior results regarding patient care and hospital savings, hospitals and monitoring centers are seeking to implement new procedures that align with the MCT system. We provide you with the latest medical technology practices and solutions to help you scale with your hardware and allow it to become Mobile Cardiac Telemetry (MCT) compatible. We have created the World's First HIPAA-Compliant, Secure, Cloud-Based Cardiac Management System, accessible from any mobile device and equipped with proprietary analytics to help you target a larger group of cardiac applications and to foster your operations growth. To know more about our service and possible ways of collaboration, please Contact Us now. CardioDiagnostics targets institutional investors who believe in the company's technology, team, and vision. CardioDiagnostics partners with select investors who bring their offerings beyond the dollar value. If you are interested in knowing more about our latest technologies and investment opportunities, please feel free to Contact Us. Market Size The global cardiac monitoring market is expected to grow to $23.3 Billion in 2017 (Markets and Markets, 2014). In 2010, it is estimated that around 2.2 million patients used remote monitoring in the U.S. alone. This number is expected to reach 6 millions in 2016 (Markets and Markets, 2014). These figures clearly show the market opportunity for the cutting-edge monitoring technologies developed by CardioDiagnostics. We are Raising Funds. If you wish to be part of the game, do not hesitate to Contact Us. Check out the latest Articles on the benefits and the growing need for Wireless Cardiac Monitoring Solutions. CardioDiagnostics Technologies CardioDiagnostics developed the World's First HIPAA-Compliant, Secure, Cloud-Based Cardiac Management System accessible from any internet connected device. CardioDiagnostics continues to develop proprietary technologies addressed at the larger audience to help prevent cardiac conditions. That tragedy, which doctors said could have been avoided if there had been a way to monitor his heart, prompted Sankari to study cardiac electrical activity. The Lebanese entrepreneur went on to found a pioneering medical technology company, CardioDiagnostics, specializing in developing cardiac monitoring products and services for doctors and patients. Unlike a traditional portable recording device, which heart patients strap on for a day or two to record heart activity that their doctor analyzes at their next appointment, the CardioDiagnostics innovation allows cardiologists to monitor patients remotely for extended periods of time. Perhaps most importantly, physicians have real-time access to that data through monitoring centers in the United States and Lebanon. Read More This research is meant to establish if a patient monitored with mobile cardiac telemetry (MCT) sees different outcomes regarding diagnostic yield of arrhythmia, therapeutic management through the use of antiarrhythmic drugs, and cardiovascular costs incurred in the hospital setting when compared with more traditional monitoring devices, such as the Holter or the Event monitor. Study: A retrospective analysis was conducted spanning 57 months of claims data from January 2007 to September 2011 pertaining to 200,000+ patients, of whom 14,000 used MCT only, 54,000 an Event monitor only, and 163,000 a Holter monitor only. Conclusion: First, the diagnostic yield of patients monitored with MCT is 61%, that is significantly higher than that of patients that use the Event monitor (23%) or the Holter monitor (24%). Second, patients naive to antiarrhythmic drugs initiate drug therapy after monitoring at the following rates: 61% for patients that use MCT compared with 39% for patients that use the Event and 43% for patients that use the Holter. Third, there are very significant inpatient cardiovascular savings (in the tens of thousands of dollars) for patients that undergo ablation, coronary artery bypass graft (CABG) and valve septa. Savings are more modest but nonetheless significant when it comes to the heart/pericardium procedure. Given the superior outcome of MCT regarding both patient care and hospital savings, hospitals only stand to gain by enforcing protocols that favor the MCT system over the Event or the Holter monitor. Read More In the article "Contemporary Reviews in Cardiovascular Medicine" by M.D. Peter Zimetbaum and Alena Goldman, a study was conducted to compare real- time telemetry with 24-hour Holters. Study: One of the studies that were conducted involves one randomized controlled trial involving 266 patients with a high clinical suspicion for a malignant arrhythmia, history of syncope, presyncope, or severe infrequent palpitations and a no-diagnostic 24-hour Holter. Conclusion: 41.4% of patients in the real-time telemetry group had detection of a clinically significant arrhythmia. Another two Prospective studies were done using MCOT and resulted with a diagnostic yield of 88% and 50%. Read More Atrial fibrillation is a leading cause of recurrent stroke. Early detection, diagnosis and treatment are critical. Study: A study was conducted that involves patients without known atrial fibrillation who had a cryptogenic ischemic stroke within the previous 6 months. The patients undergo additional noninvasive ambulatory ECG monitoring with either a 30-day event-triggered recorder (intervention group) or a conventional 24-hour monitor (control group). Conclusion: Noninvasive ambulatory ECG monitoring for a target of 30 days significantly improved the detection of atrial fibrillation by a factor of more than five and nearly doubled the rate of anticoagulant treatment, as compared with the standard practice of short-duration ECG monitoring. Read More According to research conducted by the American Heart Association, roughly 5.1 million Americans have heart failure. Approximately half of the patients who experience the disease die within five years of diagnosis. Study: A study conducted by Pennsylvania hospital system Geisinger Health Plan aimed at quantifying the benefit and value of remote patient monitoring in diagnosing patients with heart failure. The research was restricted to 541 patients. These patients remained on the plan for a full 70-month study (which included a year of data prior to the start of the intervention). The study had no control groups; instead each member's claims data for months they were enrolled in the intervention was compared to claims data when they were not. Conclusion: Study shows that the remote monitoring program reduces 30-day readmissions by 44 percent and 90-day readmissions by 38 percent. Overall costs are reduced by 11 percent. Read More We highly Invest in our talents and believe that every single member of our family makes a big contribution towards our success. To apply, kindly send your CV to: info@cardiodiagnostics.net Majors: Computer Engineering/Electrical Engineering/Software Engineering/Computer Science Years Of Experience: (0-10) years Number of Positions: 1

TAGS:Reinventing CardioDiagnostics Care 

<<< Thank you for your visit >>>

CardioDiagnostics offers cloud-based cardiac monitoring solutions, allowing patients to be monitored anytime, anywhere for extended periods of time.

Hot Websites